{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:33:56Z","timestamp":1783578836014,"version":"3.55.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100012476","name":"Fundamental Research Funds for Central Universities of the Central South University","doi-asserted-by":"publisher","award":["2024ZZTS0988"],"award-info":[{"award-number":["2024ZZTS0988"]}],"id":[{"id":"10.13039\/501100012476","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2023JJ60503"],"award-info":[{"award-number":["2023JJ60503"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"name":"China Chronic Rheumatic autoimmune disease Research Project from China Primary Health Care Foundation"},{"name":"Hunan Province Science and Technology Innovation Talent Program","award":["2023SK4015"],"award-info":[{"award-number":["2023SK4015"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s10067-025-07368-1","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:26:28Z","timestamp":1740126388000},"page":"1597-1606","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Sequential biologic therapy in the treatment of active psoriatic arthritis in China: a cost-effectiveness analysis"],"prefix":"10.1007","volume":"44","author":[{"given":"Ouyang","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kehui","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongqing","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liubao","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5315-8141","authenticated-orcid":false,"given":"Xiaomin","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"issue":"5","key":"7368_CR1","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.3390\/ijms24054901","volume":"24","author":"AB Azuaga","year":"2023","unstructured":"Azuaga AB, Ram\u00edrez J, Ca\u00f1ete JD (2023) Psoriatic arthritis: pathogenesis and targeted therapies. Int J Mol Sci 24(5):4901","journal-title":"Int J Mol Sci"},{"issue":"1","key":"7368_CR2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","volume":"80","author":"F Alinaghi","year":"2019","unstructured":"Alinaghi F, Calov M, Kristensen LE et al (2019) Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol 80(1):251-265.e19","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"7368_CR3","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1093\/rheumatology\/ker370","volume":"51","author":"R Li","year":"2012","unstructured":"Li R, Sun J, Ren LM, Wang HY, Liu WH, Zhang XW et al (2012) Epidemiology of eight common rheumatic diseases in China: a large-scale cross-sectional survey in Beijing. Rheumatology (Oxford) 51(4):721\u2013729","journal-title":"Rheumatology (Oxford)"},{"key":"7368_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40744-016-0029-z","volume":"3","author":"A Kavanaugh","year":"2016","unstructured":"Kavanaugh A, Helliwell P, Ritchlin CT (2016) Psoriatic arthritis and burden of disease: patient perspectives from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Rheumatol Ther 3:91\u2013102","journal-title":"Rheumatol Ther"},{"issue":"8","key":"7368_CR5","first-page":"883","volume":"61","author":"Y Su","year":"2022","unstructured":"Su Y, Wang CH, Gao JF, Zhang FX, Lin JY, Zhang LY, Zhao Y (2022) Recommendations for diagnosis and treatment of psoriatic arthritis in China. Zhonghua Nei Ke Za Zhi 61(8):883\u2013892","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"6","key":"7368_CR6","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A, Wit MD, Mclnnes I, Dougados M et al (2020) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 79(6):700\u2013712","journal-title":"Ann Rheum Dis"},{"key":"7368_CR7","unstructured":"Gang W, Xuejun Z (2021) Guidelines for biologic therapy of psoriasis in China (2021). Chin J Dermatol 54(12)"},{"issue":"9999","key":"7368_CR8","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P et al (2015) Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 386(9999):1137\u20131146","journal-title":"Lancet"},{"issue":"10","key":"7368_CR9","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1002\/art.21306","volume":"52","author":"PJ Mease","year":"2005","unstructured":"Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH et al (2005) Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52(10):3279\u20133289","journal-title":"Arthritis Rheum"},{"issue":"10230","key":"7368_CR10","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","volume":"395","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Rahman P, Gottlieb AB, Kollmeier AP, Hsia EC, Xu XL et al (2020) Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 395(10230):1126\u20131136","journal-title":"Lancet"},{"issue":"9894","key":"7368_CR11","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","volume":"382","author":"IB McInnes","year":"2013","unstructured":"McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C et al (2013) Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382(9894):780\u2013789","journal-title":"Lancet"},{"issue":"6","key":"7368_CR12","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"C Ritchlin","year":"2014","unstructured":"Ritchlin C, Rahman P, Kavanaugh A, Mclnnes IB, Puig L, Li S et al (2014) Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 73(6):990\u2013999","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"7368_CR13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler C et al (2017) Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis 76(1):79\u201387","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"7368_CR14","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1136\/ard.2006.058339","volume":"66","author":"A Kavanaugh","year":"2007","unstructured":"Kavanaugh A, Krueger GG, Beutler A, Guzzo C, Zhou B, Dooley LT et al (2007) Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 66(4):498\u2013505","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"7368_CR15","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1002\/art.20335","volume":"50","author":"PJ Mease","year":"2004","unstructured":"Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P et al (2004) Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 50(7):2264\u20132272","journal-title":"Arthritis Rheum"},{"issue":"5","key":"7368_CR16","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1093\/rheumatology\/keab119","volume":"60","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, McInnes IB, Tam LS, Eaton K, Peterson S, Schubert A et al (2021) Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. Rheumatology (Oxford) 60(5):2109\u20132121","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"7368_CR17","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/j.1524-4733.2010.00775.x","volume":"13","author":"JJ Caro","year":"2010","unstructured":"Caro JJ, M\u00f6ller J, Getsios D (2010) Discrete event simulation: the preferred technique for health economic evaluations? Value Health 13(8):1056\u20131060","journal-title":"Value Health"},{"issue":"6","key":"7368_CR18","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.jval.2020.01.010","volume":"23","author":"K Kongpakwattana","year":"2020","unstructured":"Kongpakwattana K, Chaiyakunapruk N (2020) Application of discrete-event simulation in health technology assessment: a cost-effectiveness analysis of Alzheimer\u2019s disease treatment using real-world evidence in Thailand. Value Health 23(6):710\u2013718","journal-title":"Value Health"},{"issue":"12","key":"7368_CR19","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s40273-020-00961-z","volume":"38","author":"L Tian","year":"2020","unstructured":"Tian L, Xiong X, Guo Q, Chen Y, Wang L, Dong P et al (2020) Cost-effectiveness of tofacitinib for patients with moderate-to-severe rheumatoid arthritis in China. Pharmacoeconomics 38(12):1345\u20131358","journal-title":"Pharmacoeconomics"},{"key":"7368_CR20","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s40744-016-0042-2","volume":"3","author":"V Strand","year":"2016","unstructured":"Strand V, Husni E, Griffith J, Zhou ZY, Signorovitch J, Ganguli A (2016) Economic evaluation of timely versus delayed use of tumor necrosis factor inhibitors for treatment of psoriatic arthritis in the US. Rheumatol Ther 3:305\u2013322","journal-title":"Rheumatol Ther"},{"issue":"7","key":"7368_CR21","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s40273-018-0674-x","volume":"36","author":"V Buchanan","year":"2018","unstructured":"Buchanan V, Sullivan W, Graham C, Miles L, Jugl SM, Gunda P et al (2018) Cost effectiveness of secukinumab for the treatment of active psoriatic arthritis in the UK. Pharmacoeconomics 36(7):867\u2013878","journal-title":"Pharmacoeconomics"},{"issue":"56","key":"7368_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta21560","volume":"21","author":"M Corbett","year":"2017","unstructured":"Corbett M, Chehadah F, Biswas M, Moe-Byrne T, Palmer S et al (2017) Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation. Health Technol Assess 21(56):1\u2013326","journal-title":"Health Technol Assess"},{"issue":"10","key":"7368_CR23","first-page":"i","volume":"15","author":"M Rodgers","year":"2011","unstructured":"Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T et al (2011) Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess (Winchester, England) 15(10):i\u2013329","journal-title":"Health Technol Assess (Winchester, England)"},{"issue":"2","key":"7368_CR24","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jval.2014.10.013","volume":"18","author":"JJ Carlson","year":"2015","unstructured":"Carlson JJ, Ogale S, Dejonckheere F, Sullivan SD (2015) Economic evaluation of tocilizumab monotherapy compared to adalimumab monotherapy in the treatment of severe active rheumatoid arthritis. Value Health 18(2):173\u2013179","journal-title":"Value Health"},{"issue":"1","key":"7368_CR25","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"JB Galloway","year":"2011","unstructured":"Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP et al (2011) Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 50(1):124\u2013131","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"7368_CR26","first-page":"CD08794","volume":"2011","author":"JA Singh","year":"2011","unstructured":"Singh JA, Wells GA, Christensen R, Ghogomu ET, Maxwell L, Macdonald JK et al (2011) Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011(2):CD08794","journal-title":"Cochrane Database Syst Rev"},{"key":"7368_CR27","unstructured":"WHO [Internet]. China Life Table, Inc.; Available from: https:\/\/www.who.int\/data\/gho\/data\/indicators\/indicator-details\/GHO\/gho-ghe-life-tables-by-country. Accessed 27 Sep, 2023"},{"issue":"10","key":"7368_CR28","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1002\/art.1780401021","volume":"40","author":"K Wong","year":"1997","unstructured":"Wong K, Gladman DD, Husted J, Long JA, Farewell VT (1997) Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 40(10):1868\u201372","journal-title":"Arthritis Rheum"},{"issue":"4","key":"7368_CR29","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/13696998.2019.1707208","volume":"23","author":"S Capri","year":"2020","unstructured":"Capri S, Migliore A, Loconsole F, Barbieri M (2020) A cost-effectiveness and budget impact analysis of apremilast in patients with psoriatic arthritis in Italy. J Med Econ 23(4):353\u2013361","journal-title":"J Med Econ"},{"key":"7368_CR30","unstructured":"YaoZh[Internet]. Inquiry of drug bid information. Available from: https:\/\/www.db.yaozh.com\/yaopinzhongbiao. Accessed 26 Oct, 2023"},{"key":"7368_CR31","unstructured":"Catalog of current medical service price items in Hunan Province (2022). Available from: https:\/\/ybj.hunan.gov.cn\/ybj\/first113541\/firstF\/f2113606\/202211\/t20221110_29122074.html Accessed 26 Oct, 2023"},{"issue":"5 Suppl 31","key":"7368_CR32","first-page":"S94","volume":"21","author":"DP Symmons","year":"2003","unstructured":"Symmons DP, Silman AJ (2003) The Norfolk Arthritis Register (NOAR). Clin Exp Rheumatol 21(5 Suppl 31):S94\u2013S99","journal-title":"Clin Exp Rheumatol"},{"issue":"06","key":"7368_CR33","first-page":"27","volume":"18","author":"C LiLi","year":"2023","unstructured":"LiLi C, Xin C, Bin Z, Zigang L, Yang Y, Fan Y (2023) Cost-effectiveness of Apremilast tablets in the treatment of moderate to severe plaque psoriasis. China Pharmacoeconomics 18(06):27\u201332","journal-title":"China Pharmacoeconomics"},{"issue":"3","key":"7368_CR34","first-page":"7","volume":"6","author":"Task Group of the Chinese Guidelines for Pharmacoeconomic Evaluations","year":"2011","unstructured":"Task Group of the Chinese Guidelines for Pharmacoeconomic Evaluations (2011) China guidelines for pharmacoeconomic evaluations. Chin J Pharm Econ 6(3):7\u201348","journal-title":"Chin J Pharm Econ"},{"key":"7368_CR35","unstructured":"The World Bank [Internet]. GDP per capita (current US$): China. Available from : https:\/\/www.data.worldbank.org\/indicator\/NY.GDP.PCAP.CD?locations=CN. Accessed Dec 16, 2023"},{"issue":"2","key":"7368_CR36","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00108-021-01259-8","volume":"63","author":"T Zander","year":"2022","unstructured":"Zander T, Hallek M (2022) Was muss der Internist bei Patienten unter Biologikabehandlung beachten?\u202f: Infektionen und Autoimmunph\u00e4nomene [What should specialist in internal medicine be aware of in patients treated with biologics?\u202f: Infections and autoimmune phenomena]. Internist (Berl) 63(2):165\u2013170","journal-title":"Internist (Berl)"},{"issue":"5","key":"7368_CR37","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1080\/14740338.2019.1612872","volume":"18","author":"F Cantini","year":"2019","unstructured":"Cantini F, Niccoli L, Capone A, Petrone L, Goletti D (2019) Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice. Expert Opin Drug Saf 18(5):415\u2013425","journal-title":"Expert Opin Drug Saf"},{"issue":"12","key":"7368_CR38","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1093\/rheumatology\/keaa449","volume":"59","author":"Y Xu","year":"2020","unstructured":"Xu Y, Li Y, Dong M et al (2020) Association of previous treatment with anti-tumour necrosis factor inhibitors with the effectiveness of secukinumab in the treatment of psoriatic arthritis: systematic review and meta-analysis. Rheumatology (Oxford) 59(12):3657\u20133665","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"7368_CR39","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1111\/ced.15237","volume":"47","author":"Y Xie","year":"2022","unstructured":"Xie Y, Liu Y (2022) Does previous use of tumour necrosis inhibitors change the therapeutic effect of interleukin (IL)-17 or IL-12\/23 inhibitors on psoriasis and psoriatic arthritis? Results of a systematic review. Clin Exp Dermatol 47(9):1627\u20131635","journal-title":"Clin Exp Dermatol"},{"key":"7368_CR40","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12962-018-0162-3","volume":"16","author":"T Purmonen","year":"2018","unstructured":"Purmonen T, Puolakka K, Bhattacharyya D, Jain M, Martikainen J (2018) Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective. Cost Eff Resour Alloc 16:56","journal-title":"Cost Eff Resour Alloc"},{"issue":"2","key":"7368_CR41","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/13696998.2017.1384737","volume":"21","author":"R Goeree","year":"2018","unstructured":"Goeree R, Chiva-Razavi S, Gunda P, Graham CN, Miles L, Nikoglou E et al (2018) Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective. J Med Econ 21(2):163\u2013173","journal-title":"J Med Econ"},{"issue":"4","key":"7368_CR42","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s41669-020-00202-1","volume":"4","author":"B Schweikert","year":"2020","unstructured":"Schweikert B, Malmberg C, \u00c5kerborg \u00d6 et al (2020) Cost-Effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab in the treatment of active psoriatic arthritis with concomitant moderate-to-severe psoriasis in the UK. Pharmacoecon Open 4(4):635\u2013648","journal-title":"Pharmacoecon Open"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07368-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07368-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07368-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T10:55:09Z","timestamp":1744455309000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07368-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["7368"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07368-1","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"assertion":[{"value":"25 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The manuscript does not contain clinical studies or patient data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}